Novo Nordisk plots $4.1 billion in U.S. factory amid Ozempic shortage, the same day it pulled out of its Ireland development project [Fortune]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Fortune
The project in Clayton, North Carolina, will double the company's production footprint in the US, adding 1.4 million square feet of space for the final stages of manufacturing in which Novo's medicines are filled into injector pens and prepared for consumers. The facility will add 1,000 jobs, the Danish drugmaker said Monday. Shares of Novo rose slightly in early trading on Tuesday. The stock is up nearly 85% in the past year. The new US site is the latest in a series of multibillion-dollar investments into ratcheting up supply for diabetes drug Ozempic and weight-loss medicine Wegovy, which have propelled Novo into the limelight and made it Europe's biggest company. Novo said it now plans to pour some $6.8 billion into production investments this year, up from $3.9 billion in 2023. Novo is buying capacity as well as building its own. The company agreed earlier this year to acquire three of contract manufacturer Catalent Inc.'s factories for $11 billion Rival Eli Lilly & Co.
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Catalent, Inc. (NYSE: CTLT) had its price target raised by analysts at Barclays PLC from $47.00 to $63.00. They now have an "equal weight" rating on the stock.MarketBeat
- Nucleic Acid Therapeutics CDMO Market Research Report 2024-2034 Featuring Strategic Analysis of Lonza Group, Catalent, and Thermo Fisher Scientific Among Others [Yahoo! Finance]Yahoo! Finance
- Sarepta cut to Neutral at Citi on risks to valuation [Seeking Alpha]Seeking Alpha
- Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies [Yahoo! Finance]Yahoo! Finance
- Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy [Seeking Alpha]Seeking Alpha
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 6/5/24 - Form 4
- 6/4/24 - Form 144
- 5/29/24 - Form 8-K
- CTLT's page on the SEC website